Published in Thromb Haemost on September 26, 2012
Nlrp3-inflammasome activation in non-myeloid-derived cells aggravates diabetic nephropathy. Kidney Int (2014) 2.09
Activated Protein C Ameliorates Renal Ischemia-Reperfusion Injury by Restricting Y-Box Binding Protein-1 Ubiquitination. J Am Soc Nephrol (2015) 1.48
Thrombomodulin/activated protein C system in septic disseminated intravascular coagulation. J Intensive Care (2015) 0.91
Elevated plasma thrombomodulin and angiopoietin-2 predict the development of acute kidney injury in patients with acute myocardial infarction. Crit Care (2014) 0.86
IKKβ regulates endothelial thrombomodulin in a Klf2-dependent manner. J Thromb Haemost (2014) 0.80
The emerging role of coagulation proteases in kidney disease. Nat Rev Nephrol (2015) 0.76
Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol (2007) 8.33
Open-source genomic analysis of Shiga-toxin-producing E. coli O104:H4. N Engl J Med (2011) 7.11
Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med (2013) 5.62
RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med (2003) 5.14
Understanding RAGE, the receptor for advanced glycation end products. J Mol Med (Berl) (2005) 4.96
Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest (2004) 4.65
Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest (2004) 3.89
Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol (2010) 3.82
A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci U S A (2010) 3.80
Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol (2005) 3.57
High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation (2008) 3.46
Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med (2007) 3.35
Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci (2004) 3.31
Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med (2011) 3.28
Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med (2009) 3.24
Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med (2003) 3.17
The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med (2003) 2.94
Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med (2009) 2.80
Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med (2003) 2.61
RAGE signaling sustains inflammation and promotes tumor development. J Exp Med (2008) 2.51
A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J (2007) 2.44
RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol (2003) 2.43
Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes (2008) 2.41
Synaptopodin regulates the actin-bundling activity of alpha-actinin in an isoform-specific manner. J Clin Invest (2005) 2.39
RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis (2008) 2.33
Role of toll-like receptors 2 and 4, and the receptor for advanced glycation end products in high-mobility group box 1-induced inflammation in vivo. Shock (2009) 2.26
Pharmacologic cholinesterase inhibition improves survival in experimental sepsis. Crit Care Med (2008) 2.18
Thrombomodulin-protein C-EPCR system: integrated to regulate coagulation and inflammation. Arterioscler Thromb Vasc Biol (2004) 2.18
A role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosis. Am J Pathol (2008) 2.17
The influence of gender and sexual hormones on incidence and outcome of chronic kidney disease. Pediatr Nephrol (2011) 2.13
[Do markers of bone metabolism reflect the presence of a high- or low-turnover state of bone metabolism?]. Med Klin (Munich) (2002) 2.10
Podocyte migration during nephrotic syndrome requires a coordinated interplay between cathepsin L and alpha3 integrin. J Biol Chem (2004) 2.10
Successful treatment of DEAP-HUS with eculizumab. Pediatr Nephrol (2013) 2.00
Complement resistance of Borrelia burgdorferi correlates with the expression of BbCRASP-1, a novel linear plasmid-encoded surface protein that interacts with human factor H and FHL-1 and is unrelated to Erp proteins. J Biol Chem (2003) 1.99
Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system. Blood (2011) 1.97
A genetic Xenopus laevis tadpole model to study lymphangiogenesis. Nat Med (2005) 1.85
Essential role of survivin, an inhibitor of apoptosis protein, in T cell development, maturation, and homeostasis. J Exp Med (2003) 1.83
Low but sustained coagulation activation ameliorates glucose-induced podocyte apoptosis: protective effect of factor V Leiden in diabetic nephropathy. Blood (2011) 1.83
Glyoxalase-1 prevents mitochondrial protein modification and enhances lifespan in Caenorhabditis elegans. Aging Cell (2008) 1.81
Eculizumab and refractory membranoproliferative glomerulonephritis. N Engl J Med (2012) 1.80
An outbreak of Shiga toxin-producing Escherichia coli O104:H4 hemolytic uremic syndrome in Germany: presentation and short-term outcome in children. Clin Infect Dis (2012) 1.79
Carnosine as a protective factor in diabetic nephropathy: association with a leucine repeat of the carnosinase gene CNDP1. Diabetes (2005) 1.75
Complement in human diseases: Lessons from complement deficiencies. Mol Immunol (2009) 1.73
RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J Am Soc Nephrol (2009) 1.72
Complement inhibitor eculizumab in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol (2009) 1.70
Early clinical experiences with the new influenza A (H1N1/09). Dtsch Arztebl Int (2009) 1.65
RAGE (receptor for advanced glycation end products): a central player in the inflammatory response. Microbes Infect (2004) 1.63
Targeted reduction of advanced glycation improves renal function in obesity. Kidney Int (2011) 1.63
Coagulation and innate immune responses: can we view them separately? Blood (2009) 1.61
C3 deposition glomerulopathy due to a functional factor H defect. Kidney Int (2008) 1.61
Role of Gas6 receptors in platelet signaling during thrombus stabilization and implications for antithrombotic therapy. J Clin Invest (2005) 1.55
Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases. J Biol Chem (2008) 1.52
Microvesicles of women with gestational hypertension and preeclampsia affect human trophoblast fate and endothelial function. Hypertension (2013) 1.52
Helium/oxygen-driven albuterol nebulization in the management of children with status asthmaticus: a randomized, placebo-controlled trial. Pediatr Crit Care Med (2010) 1.48
Caveolin-1-dependent apoptosis induced by fibrin degradation products. Blood (2008) 1.47
sRAGE is elevated in septic patients and associated with patients outcome. J Surg Res (2007) 1.47
Survivin splice variants regulate the balance between proliferation and cell death. Oncogene (2005) 1.46
AGE-modified albumin containing infusion solutions boosts septicaemia and inflammation in experimental peritonitis. J Leukoc Biol (2009) 1.45
Immune evasion of Borrelia burgdorferi: mapping of a complement-inhibitor factor H-binding site of BbCRASP-3, a novel member of the Erp protein family. Eur J Immunol (2003) 1.45
C. elegans as model for the study of high glucose- mediated life span reduction. Diabetes (2009) 1.45
The Case: Renal failure in a male with Waldenström's macroglobulinemia. Kidney Int (2010) 1.44
Evidence of left ventricular contractile asynchrony by echocardiographic phase imaging in patients with type 2 diabetes mellitus and without clinically evident heart disease. Am J Cardiol (2006) 1.44
Essential role for survivin in early brain development. J Neurosci (2005) 1.44
Functional characterization of BbCRASP-2, a distinct outer membrane protein of Borrelia burgdorferi that binds host complement regulators factor H and FHL-1. Mol Microbiol (2006) 1.43
Overexpression of activated protein C is detrimental during severe experimental gram-negative sepsis (melioidosis). Crit Care Med (2013) 1.43
Effect of thiol antioxidant on body fat and insulin reactivity. J Mol Med (Berl) (2004) 1.43
Platelets contribute to postnatal occlusion of the ductus arteriosus. Nat Med (2009) 1.41
Increased proinflammatory endothelial response to S100A8/A9 after preactivation through advanced glycation end products. Cardiovasc Diabetol (2006) 1.40
Association of history of allergies and influenza-like infections with laryngeal cancer in a case-control study. Eur Arch Otorhinolaryngol (2015) 1.39
The spectrum of systemic immune alterations after murine focal ischemia: immunodepression versus immunomodulation. Stroke (2009) 1.38
Central sympatholytics prolong survival in experimental sepsis. Crit Care (2009) 1.37
Treatment of painful vertebral fractures by kyphoplasty in patients with primary osteoporosis: a prospective nonrandomized controlled study. J Bone Miner Res (2004) 1.34
An international serum standard for application in assays to detect human complement activation products. Mol Immunol (2013) 1.34
Bench-to-bedside review: The inflammation-perpetuating pattern-recognition receptor RAGE as a therapeutic target in sepsis. Crit Care (2008) 1.34
Maturing dendritic cells depend on RAGE for in vivo homing to lymph nodes. J Immunol (2008) 1.32
RAGE and Alzheimer's disease: a progression factor for amyloid-beta-induced cellular perturbation? J Alzheimers Dis (2009) 1.31
Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. J Am Soc Nephrol (2003) 1.30
Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway. Blood (2012) 1.26
The receptor for advanced glycation end products impairs host defense in pneumococcal pneumonia. J Immunol (2009) 1.25
Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia. Blood (2011) 1.24
Activation of tubular epithelial cells in diabetic nephropathy. Diabetes (2002) 1.24
Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovasc Diabetol (2007) 1.23
Promotion of importin alpha-mediated nuclear import by the phosphorylation-dependent binding of cargo protein to 14-3-3. J Cell Biol (2005) 1.23
Inflammation-associated cell cycle-independent block of apoptosis by survivin in terminally differentiated neutrophils. J Exp Med (2004) 1.22
Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15. Am J Kidney Dis (2005) 1.21
Regulation of osteoclast function and bone mass by RAGE. J Exp Med (2006) 1.21
Acute hyperglycemia causes intracellular formation of CML and activation of ras, p42/44 MAPK, and nuclear factor kappaB in PBMCs. Diabetes (2003) 1.19
Immunological characterization of the complement regulator factor H-binding CRASP and Erp proteins of Borrelia burgdorferi. Int J Med Microbiol (2004) 1.18